Prior to the CheckMate-649 study (6), many front-line treatments of GC based on PD-1/PD-L1 inhibitors failed to achieve the primary endpoint, making the value of immunotherapy for the front-line treatment of GC questionable. The gene discussed is PDCD1; the disease is gastric cancer.